Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer
- PMID: 11392495
- DOI: 10.1258/0004563011900632
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer
Similar articles
-
Prostate-specific antigen, clinical use and staging: an overview.Br J Urol. 1997 Mar;79 Suppl 1:53-60. doi: 10.1111/j.1464-410x.1997.tb00802.x. Br J Urol. 1997. PMID: 9088274 Review. No abstract available.
-
Percent free prostate-specific antigen: the next frontier in prostate-specific antigen testing.Urology. 1998 May;51(5A Suppl):98-109. doi: 10.1016/s0090-4295(98)90059-0. Urology. 1998. PMID: 9610564 Review. No abstract available.
-
Re: Clinical performance of serum isoform (-2)proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study.J Urol. 2014 Aug;192(2):421. doi: 10.1016/j.juro.2014.05.076. Epub 2014 May 14. J Urol. 2014. PMID: 25034991 No abstract available.
-
PSA and early prostate cancer detection: the importance of age-specific reference ranges.Can J Oncol. 1994 Nov;4 Suppl 1:52-6. Can J Oncol. 1994. PMID: 8853490 Review. No abstract available.
-
Serum marker %[-2]proPSA and the Prostate Health Index improve diagnostic accuracy for clinically relevant prostate cancer.BJU Int. 2016 Jan;117(1):12-3. doi: 10.1111/bju.13151. BJU Int. 2016. PMID: 26676682 No abstract available.
Cited by
-
The f/t-PSA ratio in diagnosis of in-patients and out-patients: a unitary cutoff value is not useful!World J Urol. 2009 Oct;27(5):581-5. doi: 10.1007/s00345-009-0441-x. Epub 2009 Jun 28. World J Urol. 2009. PMID: 19562347
-
Sensitivity study and optimization of a 3D electric impedance tomography prostate probe.Physiol Meas. 2009 Jun;30(6):S1-18. doi: 10.1088/0967-3334/30/6/S01. Epub 2009 Jun 2. Physiol Meas. 2009. PMID: 19491445 Free PMC article.
-
Electrical conductivity-based contrast imaging for characterizing prostatic tissues: in vivo animal feasibility study.BMC Urol. 2019 Oct 21;19(1):95. doi: 10.1186/s12894-019-0532-y. BMC Urol. 2019. PMID: 31638952 Free PMC article.
-
[PSA--Quo vadis?].Urologe A. 2009 Sep;48(9):1008, 1010, 1012-4, passim. doi: 10.1007/s00120-009-2076-3. Urologe A. 2009. PMID: 19680620 Review. German.
-
[PSA 2010--the beginning of a new era in early detection of prostate cancer].Urologe A. 2006 Sep;45 Suppl 4:127-33. doi: 10.1007/s00120-006-1173-9. Urologe A. 2006. PMID: 16941115 German. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical